We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VYVGART Argenx Australia Pty Ltd
Product name
VYVGART
Sponsor
Accepted date
Sep-2025
Active ingredients
efgartigimod alfa
Proposed indication
Vyvgart (efgartigimod alfa) is proposed as a treatment for adults with active chronic inflammatory demyelinating polyneuropathy (CIDP) that is either worsening or recurring, after prior treatment with corticosteroids or immunoglobulins. CIDP is a chronic inflmmatory condition that damages peripheral nerves, slowing or blocking nerve signals.
Application type
C (new indication)
Publication date
Sep-2025